bioXXmed AG · ISIN: DE000A0KFRJ1 · EQS - Company News

Centaur Pharmaceuticals Pvt Ltd increases sales with Woxheal® - ongoing open label marketing study in numerous Indian centres AG:

Centaur Pharmaceuticals Pvt Ltd increases sales with Woxheal® - ongoing open label marketing study in numerous Indian centres Darmstadt, 2nd February, 2023 - The Management Board of bioXXmed AG and Centaur Pharmaceuticals created a new basis for future cooperation between the two companies during a visit of Centaur in Mumbai. Centaur has increased sales since launching Woxheal® in FY 2020/2021 by 210% in FY 2021/2022 and by 84% in the first 9 months of FY 2022/2023. Local sales of approximatel...

GETTEX:T5O Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News bioXXmed AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
03 February 2023 08:09AM
Centaur Pharmaceuticals Pvt Ltd increases sales with Woxheal® - ongoing open label marketing study in numerous Indian centres AG:
DE000A0KFRJ1
Centaur Pharmaceuticals Pvt Ltd increases sales with Woxheal® - ongoing open label marketing study in numerous Indian centres Darmstadt, 2nd February, 2023 - The Management Board of bioXXmed AG and Centaur Pharmaceuticals created a new basis for future cooperation between the two companies during a visit of Centaur in Mumbai. Centaur has increase...
bioXXmed AG
About the publication
03 February 2023 08:09AM
DE000A0KFRJ1
Centaur Pharmaceuticals Pvt Ltd increases sales with Woxheal® - ongoing open label marketing study in numerous Indian centres Darmstadt, 2nd February, 2023 - The Management Board of bioXXmed AG and Centaur Pharmaceuticals created a new basis for future cooperation between the two companies during a visit of Centaur in Mumbai. Centaur has increase...
bioXXmed AG
About the publication
30 September 2021 05:04PM
Annual General Meeting of CytoTools AG votes for dismissal of all Supervisory Board members
DE000A0KFRJ1
Annual General Meeting of CytoTools AG votes for dismissal of all Supervisory Board members Darmstadt, 30 September 2021 - CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology holding company specializing in pharmaceutical and medical products, today held its Annual General Meeting in virtual form. Of the company's share capital of EUR 4,028,000.00, ...
CytoTools AG
About the publication
30 September 2021 04:44PM
Supervisory Board of CytoTools AG announces the retirement of the two members of the Management Board according to schedule
DE000A0KFRJ1
Supervisory Board of CytoTools AG announces the retirement of the two members of the Management Board according to schedule - Management Board members Dr. Freyberg and Dr. Kaiser not available for contract extensions after being voted out of office by the Supervisory Board - Management Board contracts expire by rotation today Darmstadt, 30 Septem...
CytoTools AG
About the publication
29 September 2021 03:48PM
CytoTools AG considers complete change of Management Board and Supervisory Board possible as a result of the Annual General Meeting on 30.09.2021
DE000A0KFRJ1
CytoTools AG considers complete change of Management Board and Supervisory Board possible as a result of the Annual General Meeting on 30.09.2021 Darmstadt, 29 September 2021 - CytoTools AG has invited to the ordinary (virtual) shareholders' meeting for September 30, 2021. Under agenda item 8, the Annual General Meeting is to vote on the proposal ...
CytoTools AG
About the publication
29 September 2021 11:50AM
CytoTools Reports Progress of DermaPro(R) Phase III Study in Europe and Provides Operational Status Update
DE000A0KFRJ1
CytoTools Reports Progress of DermaPro(R) Phase III Study in Europe and Provides Operational Status Update - Good progress in patient recruitment for Phase III study despite unforeseen delays due to COVID-19 - Sales of Woxheal(R) gaining significant momentum since September - Further development steps of DPOCL inhalation therapy suspended as a prec...
CytoTools AG
About the publication
29 June 2021 04:24PM
CytoTools cures resolution of 2020 Annual General Meeting with proposed capital increase
DE000A0KFRJ1
CytoTools cures resolution of 2020 Annual General Meeting with proposed capital increase - Resolution on added items to the 2020 agenda proved to be unfeasible from a technical point of view - Proposal to the 2021 Annual General Meeting is essentially the same as the resolution adopted in 2020 Darmstadt, 29 June 2021 - CytoTools AG (ISIN DE000A0KF...
CytoTools AG
About the publication
21 June 2021 09:30AM
CytoTools Q1 Trading Update: Treatment numbers in India slightly above previous quarter despite significant pandemic impact
DE000A0KFRJ1
CytoTools Q1 Trading Update: Treatment numbers in India slightly above previous quarter despite significant pandemic impact - Over 10,000 use cases in Q1 despite tough lockdown in India - Expansion into Africa following provisional approval of Woxheal in Kenya Darmstadt, 21 June 2021 - CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology holding comp...
CytoTools AG
About the publication
26 April 2021 09:48AM
CytoTools signs collaboration agreement to develop inhalation therapy for viral infections such as COVID-19 and influenza
DE000A0KFRJ1
CytoTools signs collaboration agreement to develop inhalation therapy for viral infections such as COVID-19 and influenza - Cooperation with medical technology specialists for inhalative applications - Regulatory approval with early out-licensing targeted - Completion of further development steps planned by end of third quarter Darmstadt, 26 April...
CytoTools AG
About the publication
21 December 2020 02:02PM
CytoTools receives confirmation of efficacy of DPCOL also against influenza viruses
DE000A0KFRJ1
CytoTools receives confirmation of efficacy of DPCOL also against influenza viruses - Virus-killing effect of DPOCL also confirmed with regard to influenza viruses - Novel therapeutic approach thus also of high commercial interest beyond Corona pandemic - Final results report on Sars-CoV-2 virus confirms efficacy of more than 95 percent Darmstadt,...
CytoTools AG
About the publication
07 December 2020 04:20PM
Supervisory Board of CytoTools AG expresses trust in the Management Board after the Annual General Meeting
DE000A0KFRJ1
Supervisory Board of CytoTools AG expresses trust in the Management Board after the Annual General Meeting - More than 98 percent of the shareholders represented support the company's current strategy - Shareholder group blocks large parts of the agenda with capital majority - Objection of two shareholders against capital measure significantly belo...
CytoTools AG
About the publication
18 November 2020 09:20AM
CytoTools subsidiary completes establishment of German production and starts own production of DPOCL in Europe for the first time
DE000A0KFRJ1
CytoTools subsidiary completes establishment of German production and starts own production of DPOCL in Europe for the first time - Production notified to the responsible regional council in accordance with the German Drug Law - DermaTools is allowed to produce DPOCL for the European market - In-house production is used directly to manufacture the ...
CytoTools AG
About the publication
13 November 2020 09:35AM
Efficacy of DPOCL in COVID-19 confirmed by the Institute of Medical Virology at Frankfurt University Hospital
DE000A0KFRJ1
Efficacy of DPOCL in COVID-19 confirmed by the Institute of Medical Virology at Frankfurt University Hospital - Virus-killing effect of DPOCL on SARS-CoV-2 pathogens confirmed in test series - New therapeutic approach to protect against infection by repeated daily inhalation - Search for project partner for Fast Track approval and market launch sta...
CytoTools AG
About the publication
29 October 2020 09:47AM
CytoTools starts phase III study of DermaPro in Europe
DE000A0KFRJ1
CytoTools starts phase III study of DermaPro in Europe - Study start in Germany in October and in up to seven other countries in the coming months - High prospects of success after approval and market launch in India - Sale of treasury shares generates extraordinary profit of EUR 0.33 million and creates additional financial leeway Darmstadt, 29 O...
CytoTools AG
About the publication
15 October 2020 04:00PM
CytoTools positions itself for the admission of new investors by extending the agenda of the coming general meeting
DE000A0KFRJ1
CytoTools positions itself for the admission of new investors by extending the agenda of the coming general meeting - Postponement of the Annual General Meeting for comprehensive preparation of strategic steps - Extension of the agenda by new authorized capital - New strategic and institutional investors support the company's current course Darmst...
CytoTools AG
About the publication
06 October 2020 09:30AM
CytoTools secures financing of the phase III study and appoints Chief Financial Officer
DE000A0KFRJ1
CytoTools secures financing of the phase III study and appoints Chief Financial Officer - Full financing of the Phase III study secured after registration of the capital increase - Marc Herwick appointed Chief Financial Officer of CytoTools AG Darmstadt, 6 October 2020 - The Management Board of CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology hol...
CytoTools AG
About the publication
17 September 2020 10:45AM
CytoTools examines the effectiveness of its patented active substance DPOCL in COVID-19 infections
DE000A0KFRJ1
CytoTools examines the effectiveness of its patented active substance DPOCL in COVID-19 infections - Novel therapeutic approach for easy treatment of COVID-19 with DPOCL - Proven active ingredient is delivered directly to the lungs as an inhalable aerosol - Anti-viral effect of DPOCL demonstrated in first cellular test systems Darmstadt, 17 Septem...
CytoTools AG
About the publication
03 September 2020 10:47AM
CytoTools partner Centaur Pharmaceuticals starts marketing the active substance DPOCL in India
DE000A0KFRJ1
CytoTools partner Centaur Pharmaceuticals starts marketing the active substance DPOCL in India - Scientific market launch program of DPOCL under the brand WOXheal(R) started - Distribution via nationwide clinics chains and affiliated pharmacies - Marketing start considered promising despite pandemic-related restrictions Darmstadt, 3 September 2020...
CytoTools AG
About the publication
26 August 2020 09:48AM
CytoTools introduces new strategic investor and restructures capital market communication
DE000A0KFRJ1
CytoTools introduces new strategic investor and restructures capital market communication- Pharma-CDMO Klocke Group participates as new strategic investor - Milestone for financing of phase III of the approval process for DermaPro(R) - Professionalization of investor relations for an improved capital market positioning through the signing of Interi...
CytoTools AG
About the publication
More bioXXmed AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN